Coronavirus (COVID-19)
Learn more
May 09, 2017
Sponsor: Janssen Research & Development, LLC
Number: 39039039STM4001 (BAY 59-7939)
Eligible patients who enroll in the study will be randomly assigned (by chance) to this multicenter, double-blind, placebo-controlled, parallel-group, superiority study comparing the efficacy and safety of Rivaroxaban with placebo for primary prophylaxis of venous thromboembolism (VTE) in ambulatory adult participants, with various cancer types who are scheduled to initiate systemic cancer therapy.
Who’s eligible:
Available at: Backus Hospital- Eastern Connecticut Hematology and Oncology.
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.